Related references
Note: Only part of the references are listed.Cancer vaccines Identification of biomarkers predictive of clinical efficacy
Richard Harrop
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax)
Richard Harrop et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients
Richard Harrop et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Delineation of a Cellular Hierarchy in Lung Cancer Reveals an Oncofetal Antigen Expressed on Tumor-Initiating Cells
Marc Damelin et al.
CANCER RESEARCH (2011)
Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Robert J. Amato et al.
CLINICAL CANCER RESEARCH (2010)
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Philip W. Kantoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression
Ravi A. Madan et al.
ONCOLOGIST (2010)
Vaccination of Patients With Metastatic Renal Cancer With Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Interferon-α
Robert E. Hawkins et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Vaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Alone or Administered in Combination With Interferon-α (IFN-α) A Phase 2 Trial
Robert J. Amato et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma
Howard L. Kaufman et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
Vaccination of Renal Cell Cancer Patients with Modified Vaccinia Ankara Delivering Tumor Antigen 5T4 (TroVax) Administered with Interleukin 2: A Phase II Trial
Robert J. Amato et al.
CLINICAL CANCER RESEARCH (2008)
Combination of docetaxel and recombinant vaccine enhances T-Cell responses and antitumor activity: Effects of docetaxel on immune enhancement
Charlie T. Garnett et al.
CLINICAL CANCER RESEARCH (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Vaccination of prostate cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) - A phase 2 trial
Robert J. Amato et al.
JOURNAL OF IMMUNOTHERAPY (2008)
An MVA-based Vaccine Targeting the Oncofetal Antigen 5T4 in Patients Undergoing Surgical Resection of Colorectal Cancer Liver Metastases
Eyad Elkord et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses
Richard Harrop et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Vaccination of colorectal cancer patients with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses
Richard Harrop et al.
CLINICAL CANCER RESEARCH (2007)
Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: A phase I/II trial
Richard Harrop et al.
CLINICAL CANCER RESEARCH (2006)
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer
PM Arlen et al.
CLINICAL CANCER RESEARCH (2006)
Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer
R Dagher et al.
CLINICAL CANCER RESEARCH (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The immunological effects of taxanes
OTM Chan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2000)
Share Paper
